Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RDM1 pseudogene 4 (RDM1P4) is classified as a *processed pseudogene* located in the human genome. Pseudogenes are segments of DNA similar to known genes but are generally non-functional in terms of protein-coding due to mutations, truncations, or absence of regulatory elements. While the protein-coding RDM1 gene (RAD52 motif-containing protein 1) plays important roles in DNA damage repair, cell cycle regulation, and cancer biology[1], RDM1P4 does not encode a functional protein. Like other human pseudogenes, RDM1P4 could potentially regulate gene expression at the RNA level, for example by acting as a *competitive endogenous RNA (ceRNA)*, miRNA decoy, or modulator of its parental gene[3][9][10]. However, there is no direct experimental evidence for RDM1P4 having such functions, nor is it an established therapeutic or diagnostic target. Therefore, RDM1P4 is not considered a classic drug target, receptor, enzyme, or transporter; its direct clinical or therapeutic relevance remains unknown. Key points: - RDM1P4 is a pseudogene, not a protein-coding gene or druggable target. - No specific functional, disease, or drug interaction data are available for this pseudogene. - Its *putative* functions (if any) would likely be based on general mechanisms attributed to pseudogenes, such as RNA-based regulation. - The protein-coding parent gene RDM1 is biologically significant (cancer, DNA repair)[1], but this does not extend to RDM1P4 itself in current scientific knowledge. If you need a canonical, protein-coding therapeutic target, you may be searching for **RAD52 motif-containing protein 1 (RDM1)** rather than this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RDM1 pseudogene 4 (RDM1P4).